Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 23;21(1):962.
doi: 10.1186/s13063-020-04893-z.

An investigation into the factors affecting investigator-initiated trial start-up in Ireland

Lauren Leddy  1 , Prasanth Sukumar  1 , Lydia O'Sullivan  1   2 , Fionnuala Keane  3 , Declan Devane  2   4 , Peter Doran  5
Affiliations

An investigation into the factors affecting investigator-initiated trial start-up in Ireland

Lauren Leddy et al. Trials. .

Abstract

Background: In common with many countries, Ireland has seen an increasing trend in the number of clinical trials conducted over the past few years. Yet, as elsewhere, trialists in Ireland face several problems and barriers in the starting-up of clinical trials. These barriers impede trial activity significantly, with consequent impacts on patient care. It is critical to understand these issues, to develop approaches to facilitate trial start up. This study identifies the challenges in conducting clinical trials in Ireland and specifically the contractual, ethical, logistical, and regulatory barriers that hinder the start-up of investigator-led trials in Ireland.

Methods: Data for this study were collected in two stages. In the first stage, a survey was conducted among trialists in Ireland. A total of 44 trialists responded to the survey, and information was collected about their experience in conducting clinical trials, the scale and nature of their most recently completed trial, and the details of specific barriers they encountered during the starting-up of the trial. In the second stage, nine semi-structured interviews were conducted with the awardees of 2018 Irish Health Research Board's Definitive Intervention Feasibility Award. These interviews facilitated a deeper exploration of issues and problems in conducting clinical trials in Ireland.

Results: This study identified several issues and bottlenecks in starting-up clinical trials in Ireland with contracts and ethical approval cited as the major issues. The data shows that site identification and activation was also problematic in some cases. Several respondents reported difficulties in accessing dedicated time for protocol development and believe that support in this area can be greatly beneficial. It was reported that availability of skilled staff members like statisticians and data managers was as an issue, especially for small trials.

Conclusion: This study found that several factors impact trial initiation and progression in Ireland. Delays associated with obtaining contract and ethics approval are perceived as major barriers. Specialist supports in areas such as ethics and regulatory affairs and availability of specialised staff members in areas such as statistics and data management are key actions to enable enhanced clinical trial activity in Ireland.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Bothwell LE, Greene JA, Podolsky SH, Jones DS, Malina D. Assessing the gold standard-lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175–2181. doi: 10.1056/NEJMms1604593. - DOI - PubMed
    1. Jakobsen J. The necessity of randomized clinical trials. Br J Med Med Res. 2013;3(4):1453–1468. doi: 10.9734/BJMMR/2013/3208. - DOI
    1. Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius S, Li T, Ounpuu S, Perez AC, et al. Specific barriers to the conduct of randomized trials. Clin Trials. 2008;5(1):40–48. doi: 10.1177/1740774507087704. - DOI - PubMed
    1. Duffett M, Choong K, Foster J, Meade M, Menon K, Parker M, Cook DJ. High-quality randomized controlled trials in pediatric critical care: a survey of barriers and facilitators. Pediatr Crit Care Med. 2017;18(5):405–413. doi: 10.1097/PCC.0000000000001144. - DOI - PubMed
    1. Sertkaya A, Birkenbach A, Berlind A, Eyraud J. Examination of clinical trial costs and barriers for drug development. Washington, DC: Report, US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation; 2014. pp. 1–92.

LinkOut - more resources